Sydney Jennings

FDA approval expands Afrezza as an inhaled mealtime insulin option for pediatric patients with diabetes aged 6 years and older.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

Post hoc phase 3 analyses linked centanafadine to improved executive function and emotional regulation in adults with ADHD.

ACS updated colorectal cancer screening guidance, reaffirming screening at age 45 and adding newer stool-based and blood-based options.

Elunetirom received FDA Fast Track designation as an adjunctive therapy for bipolar depression, with phase 2 AMPLIFY-BD data expected in 2026.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

Orforglipron reduced body weight versus placebo in adults aged 65 years or older with obesity or overweight in ATTAIN-1 and ATTAIN-2.

FDA grants priority review to finerenone for adults with type 1 diabetes and chronic kidney disease based on FINE-ONE data.

Retatrutide reduced body weight by up to 28.3% at 80 weeks in adults with obesity or overweight in the phase 3 TRIUMPH-1 trial.

FDA accepted Bayer's asundexian NDA for recurrent stroke prevention after noncardioembolic ischemic stroke or TIA.

A NHANES analysis suggests a ferritin cutoff below 24 μg/L may identify more iron deficiency in children aged 5 to 14 years.

Embedding addiction treatment in a resident primary care clinic increased confidence in SUD diagnosis, medication use, and harm-reduction counseling.

A Massachusetts claims study found rising pediatric primary care visits with mental health diagnoses, led by anxiety-related care.

FDA approved baxdrostat for adults with hypertension not controlled on other agents, adding a new aldosterone-targeting option.

A 5-day course of ensitrelvir reduced symptomatic COVID-19 risk by 67% after household exposure in the phase 3 SCORPIO-PEP trial.

A large claims analysis suggests most US patients with prediabetes receive annual diabetes screening, although methods were not peer reviewed.

Global experts have redefined PCOS as PMOS, spotlighting metabolic and heart risks to speed diagnosis, reduce stigma, and improve care.

MR-100A-01 weekly contraceptive patch data will be presented ahead of an FDA decision on the investigational lower-estrogen product.

South London data show stroke rates climbing again, hitting Black communities and poorer areas hardest, and exposing gaps in prevention and follow-up.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.

DDW 2026 data show real-world, 52-week IBD outcomes with risankizumab and upadacitinib, including persistence, fewer switches, and hospital visits.

DDW 2026: Four-year LUCENT-3 data show mirikizumab maintains composite disease clearance in over 60% of UC patients, marking a first for IL-23p19 inhibitors.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Network meta-analysis suggests lumateperone add-on therapy improves MDD symptoms most, with minimal weight gain and placebo-like akathisia risk.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.